Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Women’s Health: Moving Beyond Gynecology To Sexuality

This article was originally published in Start Up

Executive Summary

Big Pharma’s exodus from women’s health has created opportunities for biotech start-ups, which hope to tap into potentially huge markets. Profiles of Evestra Pharmaceuticals, S1 Biopharma, and Sprout Pharmaceuticals.

You may also be interested in...



Sprout Pharmaceuticals Inc.

The backers of Sprout Pharmaceuticals Inc. are convinced the start-up has a drug candidate that can help women who’ve lost interest in sex feel desire again: flibanserin, a daily pill that interacts with receptors in the CNS. It was originally developed by Boehringer Ingelheim, which failed to win FDA approval in 2010 for its use in treating hypoactive sexual desire disorder, but Sprout is optimistic the clinical development work it has since put into the compound will help it win regulators’ approval.

S1 Biopharma Inc.

Pharmacological intervention for men with sexual dysfunction has become accepted medical practice, but treatment for women has lagged behind. S1 Biopharma Inc. hopes to change that: it was founded with the purpose of identifying and developing solutions for common, untreated sexual dysfunctions that affect women.

Evestra Inc.

Evestra Inc. aims to leverage its managers’ and advisors’ understanding of steroid drugs, then amplify that with expertise in medicinal chemistry, polymer science, and drug delivery. The company thinks it has the potential to create multiple women’s health products based on vaginal ring devices and new chemical entities that could be potentially safer and more effective than known ones.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT125711

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel